Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman
Stifel Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $230
Jefferies Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $154
Jazz Pharmaceuticals Price Target Maintained With a $205.00/Share by Needham
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $205
Needham Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $140 Price Target
Jazz Pharmaceuticals Analyst Ratings
Wells Fargo Maintains Jazz Pharmaceuticals(JAZZ.US) With Hold Rating, Maintains Target Price $120
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Needham Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
Stifel Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $230
TD Cowen Sticks to Its Buy Rating for Jazz Pharmaceuticals (JAZZ)
TD Cowen Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Maintains Target Price $200
JP Morgan Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $202
Jazz Pharmaceuticals Analyst Ratings
J.P. Morgan Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating, Raises Target Price to $202
Analysts' Opinions Are Mixed on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), United Therapeutics (UTHR) and Jazz Pharmaceuticals (JAZZ)
A Quick Look at Today's Ratings for Jazz Pharmaceuticals(JAZZ.US), With a Forecast Between $120 to $230